Indian Drug Regulator Orders Enhanced NDMA Monitoring for Ranitidine Amid Cancer Concerns
核心洞察
The Central Drugs Standard Control Organisation (搜索) has directed manufacturers to monitor NDMA (搜索) levels in ranitidine, a commonly prescribed acidity medication, due to cancer (搜索)-causing impurity concerns.
The Drugs Technical Advisory Board (搜索) recommended establishing a larger committee to examine all aspects of NDMA (搜索) formation, including storage conditions that may contribute to the impurity.
Manufacturers must now adopt risk-based measures including reduced shelf life, modified storage recommendations, and enhanced NDMA (搜索) testing protocols across supply chains.
The Central Drugs Standard Control Organisation (搜索) (CDSCO (搜索)) has issued new directives requiring all state and union territory drug regulators to ensure manufacturers of ranitidine monitor levels of N-nitrosodimethylamine (NDMA (搜索)), a potentially cancer (搜索)-causing impurity found in the widely prescribed acidity medication. The regulatory action follows mounting concerns about the safety profile of this commonly used drug.
The directive comes from Drugs Controller General of India Dr. Rajeev Singh Raghuvanshi, acting on recommendations from the Drugs Technical Advisory Board (搜索) (DTAB (搜索)) during its 92nd meeting held on April 28, 2025. The Board's decision was based on a comprehensive report submitted by an expert committee that was specifically constituted in December 2024 to investigate impurity concerns surrounding ranitidine.
Regulatory Response and Expert Committee Findings
Dr. Raghuvanshi stated that "the safety of ranitidine due to the presence of NDMA (搜索) impurity has been under consideration for quite some time now. This office has taken various measures from time to time." The DTAB (搜索), after detailed deliberations on the expert committee's findings, determined that a larger committee is required to examine all aspects of the NDMA issue, including storage conditions that may contribute to the formation of this impurity.
The regulatory body has also recommended that the Indian Council of Medical Research (ICMR) conduct a comprehensive study to further assess the long-term safety implications of ranitidine use in light of NDMA (搜索) presence.
New Manufacturing Requirements
Under the new guidelines, manufacturers must implement several risk-based measures to address NDMA (搜索) contamination concerns. These include limiting shelf life of ranitidine products, modifying storage recommendations, and establishing enhanced NDMA testing protocols throughout their supply chains. The CDSCO (搜索) has also suggested reducing shelf life as a precautionary measure.
Manufacturers are now required to monitor NDMA (搜索) levels in both the active pharmaceutical ingredient (API) and final formulations of ranitidine products, representing a significant shift toward more stringent quality control measures.
Clinical Perspectives on Safety Concerns
Medical experts have expressed concerns about continued ranitidine use given the availability of safer alternatives. Dr. Abhishek Shankar, an oncologist at AIIMS Delhi (搜索), noted that "ranitidine falls in the Group 2A carcinogen category, according to the International Agency for Research on Cancer (搜索) (IARC), which implies that it is a probable human carcinogen. It should not be continued in prescription when there are safer alternatives such as Famotidine and Pantoprazole available."
Dr. Lohit Chauhan, a gastroenterologist at Max Dwarka (搜索), highlighted regional prescribing patterns, stating that "ranitidine was commonly prescribed in the past. Its usage has reduced in most metro cities, but it is still prescribed in Tier 1 or 2 cities, particularly at primary healthcare centres." He emphasized that "the drug has been known to have NDMA (搜索) impurities; the FDA has also ruled out the use of this drug in large doses. The DGCI needs to set prescribed limits for NDMA levels in this drug."
Global Context and Regulatory Precedent
NDMA (搜索) is classified as a probable human carcinogen, and its presence in medications has triggered global regulatory scrutiny in recent years. Ranitidine, commonly prescribed for acid reflux (搜索) and ulcers (搜索), was withdrawn from several international markets, including the United States, after alarmingly high levels of NDMA were discovered in some product samples.
The Indian regulatory action aligns with global trends toward enhanced oversight of pharmaceutical products containing potential carcinogenic impurities, reflecting a broader commitment to patient safety and drug quality assurance.